基于网络的查确定了西塔利普丁作为一种向树突细胞的抗瘤药物
Ian-Ian Ng1, Jiaqi Zhang1, Tingzhong Tian2
1State Key Laboratory of Molecular Oncology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
Journal for immunotherapy of cancer
|March 8, 2024
概括
发现一种糖尿病药物西塔格利普丁通过增强树突细胞 (DC) 功能来增强抗瘤免疫力. 这种药物重定向为癌症免疫疗法提供了一种新的策略,通过改善对瘤的T细胞激活来改善癌症免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 树突细胞 (DC) 介导的抗原呈现对于激活瘤特异性T细胞至关重要.
- 存在有限的治疗选择,专门针对和操纵癌症免疫治疗的DC功能.
- 识别针对DCs的药物为推进癌症治疗提供了重大机会.
研究的目的:
- 确定针对癌症免疫治疗的常规1型树突细胞 (cDC1s) 的新疗法.
- 通过基于网络的查确定候选药物的抗瘤机制.
主要方法:
- 采用基于网络的方法来选针对cDC1s的治疗方法.
- 鉴定药物的抗瘤疗效和机制使用体外和体外模型进行了评估.
- 在抗原呈现期间分析了cDC1s中的转录程序.
主要成果:
- 抗糖尿病药物西塔格利普丁被确定为DC向治疗药物.
- 在小鼠模型中,西塔利普丁通过增强cDC1介导的抗原呈现和T细胞激活来表现出抗作用.
- 从机制上讲,西塔格利普丁抑制了二二甲酶4 (DPP4),防止了化学因子/细胞因子的降解,并增强了DC激活.
- 在人类结直肠癌患者中,西塔格利普丁的使用与减少瘤复发相关.
结论:
- 通过抑制DPP4,西塔利普丁通过增强cDC1功能来增强抗瘤免疫反应.
- 西塔格利普丁显示出作为向树突细胞的抗癌药物重新使用的潜力.
- 这项研究提供了一种有前途的癌症免疫治疗新策略,通过利用西塔利普丁.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
2.0K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
01:23Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186